
UK ministers are preparing to increase the amount the National Health Service pays pharmaceutical firms for medicines by up to 25%, following weeks of intensive discussions with the Trump administration and drugmakers.
The move comes as the UK faces mounting pressure to align drug prices with international standards while addressing stalled pharmaceutical investment.